(Reuters) - Eli Lilly's blockbuster diabetes drug Mounjaro and weight-loss therapy Zepbound, as well as Novo Nordisk's rival ...

GLP-1 drugs like semaglutide (Ozempic) and tirzepatide (Mounjaro) may shrink fat, but also crucial muscle mass, with little ...

HealthDay News — For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7% on average, which is lower than the percentages reported ...

Experts say supplement companies have tried to capitalize on the GLP-1 craze, putting the phrase in their product names, ...

Obesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, ...

Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...

Experts warn that the surge in demand for weight loss injections like Ozempic and Wegovy is unsustainable, with most users ...

Patients put on weight loss drugs like Ozempic and Wegovy may start regaining weight within weeks of discontinuing them, a ...

In SURMOUNT-1, people taking 15 mg of tirzepatide lost on average 22.5% of body weight -- representing a mean loss of 52 lb (24 kg) by week 72.

Researchers in a recent study discovered that people taking medications to help them lose weight might experience weight gain ...

In real-world cohort, percentage weight reduction at one year was 3.6, 6.8, and 11.9 percent with early and late discontinuation and nondiscontinuation, respectively.

Notably, 31.6% of patients receiving tirzepatide achieved at least 25% body weight loss (key secondary endpoint) compared with 16.1% of those taking semaglutide.